Seventy patients (80.5%) were treated for their IBD, including anti-TNF (45/87, 51.7%), immunosuppressant (9/87, 10.3%), 5-aminosalicylates (9/87, 10.3%), and other biologics (6/87, 6.9%). Here, TNF is linked to inflammatory bowel disease.